Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.

Primary sclerosing cholangitis (PSC), first described in the mid-1850s, is a complex liver disease that is heterogeneous in its presentation. PSC is characterized by chronic cholestasis associated with chronic inflammation of the biliary epithelium, resulting in multifocal bile duct strictures that can affect the entire biliary tree. Chronic inflammation leads to fibrosis involving the hepatic parenchyma and biliary tree, which can lead to cirrhosis and malignancy. The etiology of PSC is not fully understood, which in part explains the lack of effective medical therapy for this condition. However, we have begun to better understand the molecular pathogenesis of PSC. The recognition of specific clinical subtypes and their pattern of progression could improve phenotypic and genotypic classification of the disease. We review our current understanding of this enigmatic disorder and discuss important topics for future studies.

[1]  J. Talwalkar,et al.  The fate of indefinite and low‐grade dysplasia in ulcerative colitis and primary sclerosing cholangitis colitis before and after liver transplantation , 2013, Alimentary pharmacology & therapeutics.

[2]  M. Neurath,et al.  Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis , 2013, Hepatology.

[3]  Judy H. Cho,et al.  Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis , 2013, Nature Genetics.

[4]  K. Lindor,et al.  Inflammatory Bowel Disease in Primary Sclerosing Cholangitis: A Robust yet Changing Relationship , 2013, Inflammatory bowel diseases.

[5]  K. Reddy,et al.  Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[6]  H. Said,et al.  Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14. , 2013, The American journal of pathology.

[7]  R. Chapman,et al.  Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. , 2013, Journal of hepatology.

[8]  Y. Beyazit,et al.  Circulating CD4+CD25+ Regulatory T Cells in the Pathobiology of Ulcerative Colitis and Concurrent Primary Sclerosing Cholangitis , 2013, Digestive Diseases and Sciences.

[9]  C. Ponsioen,et al.  Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease , 2012, Inflammatory bowel diseases.

[10]  M. Färkkilä,et al.  Risk factors for complications of ERCP in primary sclerosing cholangitis , 2012, Endoscopy.

[11]  G. Greenberg,et al.  Ustekinumab induction and maintenance therapy in refractory Crohn's disease. , 2012, The New England journal of medicine.

[12]  Y. Nakanuma,et al.  Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012 , 2012, Journal of hepato-biliary-pancreatic sciences.

[13]  R. Poupon Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. , 2012, Clinics and research in hepatology and gastroenterology.

[14]  P. Trivedi,et al.  Review article: overlap syndromes and autoimmune liver disease , 2012, Alimentary pharmacology & therapeutics.

[15]  K. Boberg,et al.  Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study , 2012, Scandinavian journal of gastroenterology.

[16]  W. Sandborn,et al.  Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. , 2012, The New England journal of medicine.

[17]  D. Mould,et al.  Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose‐ranging Study , 2012, Inflammatory bowel diseases.

[18]  G. Gores,et al.  Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. , 2012, Gastroenterology.

[19]  A. Ganser,et al.  Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST) , 2012, BMC Cancer.

[20]  F. Remzi,et al.  Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  P. Dobrzanski,et al.  The many faces of Janus kinase. , 2012, Biochemical pharmacology.

[22]  M. Manns,et al.  Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders , 2012, Gut.

[23]  K. Lindor,et al.  Likelihood of Malignancy in Gallbladder Polyps and Outcomes Following Cholecystectomy in Primary Sclerosing Cholangitis , 2012, The American Journal of Gastroenterology.

[24]  K. Boberg,et al.  Inflammatory bowel disease in patients with primary sclerosing cholangitis: Clinical characterization in liver transplanted and nontransplanted patients , 2012, Inflammatory bowel diseases.

[25]  K. Boberg,et al.  High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia , 2012, Alimentary pharmacology & therapeutics.

[26]  S. Vermeire,et al.  Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long‐term single‐centre study , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[27]  T. Karlsen,et al.  Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. , 2012, World journal of gastroenterology.

[28]  G. Gores,et al.  Cancer surveillance in patients with primary sclerosing cholangitis , 2011, Hepatology.

[29]  A. Bergquist,et al.  Increased Risk of Colorectal Cancer and Dysplasia in Patients With Crohn's Colitis and Primary Sclerosing Cholangitis , 2011, Diseases of the colon and rectum.

[30]  P. Neuhaus,et al.  Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[31]  Jesse S. Voss,et al.  Primary Sclerosing Cholangitis Patients With Serial Polysomy Fluorescence In Situ Hybridization Results Are at Increased Risk of Cholangiocarcinoma , 2011, The American Journal of Gastroenterology.

[32]  K. Lindor,et al.  High‐dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis , 2011, Alimentary pharmacology & therapeutics.

[33]  M. Pollheimer,et al.  Will we ever model PSC? - "it's hard to be a PSC model!". , 2011, Clinics and research in hepatology and gastroenterology.

[34]  A. Gill,et al.  A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures , 2011, British Journal of Cancer.

[35]  A. Burroughs,et al.  Meta‐analysis: ursodeoxycholic acid for primary sclerosing cholangitis , 2011, Alimentary pharmacology & therapeutics.

[36]  T. Therneau,et al.  Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4‐associated cholangitis from cholangiocarcinoma , 2011, Hepatology.

[37]  A. Alkhatib,et al.  Comorbidities, Sphincterotomy, and Balloon Dilation Predict Post-ERCP Adverse Events in PSC Patients: Operator Experience Is Protective , 2011, Digestive Diseases and Sciences.

[38]  S. Halpern,et al.  Current Trends in Living Donor Liver Transplantation for Primary Sclerosing Cholangitis , 2011, Transplantation.

[39]  K. Lindor Farnesoid X receptor agonists for primary biliary cirrhosis , 2011, Current opinion in gastroenterology.

[40]  E. Björnsson,et al.  Primary Sclerosing Cholangitis Associated with Elevated ImmunoglobulinG4: Clinical Characteristics and Response to Therapy , 2011, American journal of therapeutics.

[41]  J. O’Shea,et al.  Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550) , 2011, The Journal of Immunology.

[42]  E. Björnsson,et al.  Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[43]  E. Cholongitas,et al.  Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? , 2011, Gut.

[44]  M. Manns,et al.  Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis , 2011, Hepatology.

[45]  S. Schreiber,et al.  Pregnancy in primary sclerosing cholangitis , 2011, Gut.

[46]  J. Boyer,et al.  Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct–ligated rats and human hepatic cells , 2011, Hepatology.

[47]  C. Weston,et al.  Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity , 2011, Hepatology.

[48]  M. Manns,et al.  Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. , 2011, Journal of hepatology.

[49]  M. Manns,et al.  Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. , 2010, Gastroenterology.

[50]  D. Morris,et al.  Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis , 2010, Journal of Inflammation.

[51]  M. Dave,et al.  Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. , 2010, Radiology.

[52]  E. Björnsson,et al.  Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in sweden , 2010, Hepatology.

[53]  R. Steele,et al.  Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002) , 2010, Gut.

[54]  C. Wijmenga,et al.  Genome-wide association analysis in primary sclerosing cholangitis. , 2010, Gastroenterology.

[55]  G. Gores,et al.  Diagnosis and management of primary sclerosing cholangitis , 2010, Hepatology.

[56]  R. Odze,et al.  AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. , 2010, Gastroenterology.

[57]  C. Lohse,et al.  IgG4+ Plasma Cell Infiltrates in Liver Explants With Primary Sclerosing Cholangitis , 2010, The American journal of surgical pathology.

[58]  O. Distler,et al.  Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies , 2009, Annals of the rheumatic diseases.

[59]  T. Sauerbruch,et al.  p-ANCAs in autoimmune liver disorders recognise human β-tubulin isotype 5 and cross-react with microbial protein FtsZ , 2009, Gut.

[60]  O. Adeyi,et al.  Liver allograft pathology: approach to interpretation of needle biopsies with clinicopathological correlation , 2009, Journal of Clinical Pathology.

[61]  S. Curbishley,et al.  Gut homing receptors on CD8 T cells are retinoic acid dependent and not maintained by liver dendritic or stellate cells. , 2009, Gastroenterology.

[62]  M. Gershwin,et al.  Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis , 2009, Seminars in Immunopathology.

[63]  R. Odze,et al.  Pathologic Features of Ulcerative Colitis in Patients With Primary Sclerosing Cholangitis: A Case-control Study , 2009, The American journal of surgical pathology.

[64]  C. Bowlus,et al.  The immunobiology of primary sclerosing cholangitis , 2009, Seminars in Immunopathology.

[65]  Thomas Korn,et al.  IL-17 and Th17 Cells. , 2009, Annual review of immunology.

[66]  U. Spengler,et al.  Atypical p-ANCA in PSC and AIH: A Hint Toward a “leaky gut”? , 2009, Clinical reviews in allergy & immunology.

[67]  Natalie J Torok,et al.  Minocycline in the Treatment of Patients With Primary Sclerosing Cholangitis: Results of a Pilot Study , 2009, The American Journal of Gastroenterology.

[68]  D. Rockey Current and future anti-fibrotic therapies for chronic liver disease. , 2008, Clinics in liver disease.

[69]  E. Cholongitas,et al.  Pathogenesis of primary sclerosing cholangitis. , 2008, Journal of hepatology.

[70]  Y. Nakanuma,et al.  Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease , 2008, Proceedings of the National Academy of Sciences.

[71]  B. Portmann,et al.  Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long‐term outcome and survival , 2008, Alimentary pharmacology & therapeutics.

[72]  R. Chapman,et al.  Etiopathogenesis of primary sclerosing cholangitis. , 2008, World journal of gastroenterology.

[73]  D. Hommes,et al.  A Double-blind, Placebo-controlled, Randomized Study of Infliximab in Primary Sclerosing Cholangitis , 2008, Journal of clinical gastroenterology.

[74]  K. Boberg,et al.  The natural history of small-duct primary sclerosing cholangitis. , 2008, Gastroenterology.

[75]  A. Bergquist,et al.  Gallbladder disease in patients with primary sclerosing cholangitis. , 2008, Journal of hepatology.

[76]  B. Petersen,et al.  Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. , 2008, Gastroenterology.

[77]  M. Haider,et al.  Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: Evaluating the role of routine magnetic resonance imaging , 2008, Hepatology.

[78]  N. LaRusso,et al.  Lipopolysaccharide disrupts tight junctions in cholangiocyte monolayers by a c-Src-, TLR4-, and LBP-dependent mechanism. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[79]  E. Björnsson,et al.  Immunoglobulin G4 associated cholangitis: Description of an emerging clinical entity based on review of the literature , 2007, Hepatology.

[80]  G. Kaplan,et al.  The Burden of Large and Small Duct Primary Sclerosing Cholangitis in Adults and Children: A Population-Based Analysis , 2007, The American Journal of Gastroenterology.

[81]  C. Verslype,et al.  Incidence, Diagnosis, and Therapy of Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis , 2007, Digestive Diseases and Sciences.

[82]  A. Bergquist,et al.  Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. , 2007, Gastroenterology.

[83]  A. Befeler,et al.  High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis , 2007, Current gastroenterology reports.

[84]  M. Trauner,et al.  MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. , 2007, Seminars in liver disease.

[85]  C. Paulusma,et al.  Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein) , 2007, Pflügers Archiv - European Journal of Physiology.

[86]  B. Sharma,et al.  Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non‐alcoholic steatohepatitis , 2006, Journal of gastroenterology and hepatology.

[87]  T. Smyrk,et al.  Elevated Serum IgG4 Concentration in Patients with Primary Sclerosing Cholangitis , 2006, The American Journal of Gastroenterology.

[88]  J. Kleibeuker,et al.  Inflammatory Bowel Disease After Liver Transplantation: Risk Factors for Recurrence and De Novo Disease , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[89]  J. Hasday,et al.  Invited review: Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease , 2006, Journal of endotoxin research.

[90]  M. Ziol,et al.  Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC , 2006, Hepatology.

[91]  S. Radley,et al.  Adenocarcinoma in an Ileoanal Pouch Formed for Ulcerative Colitis in a Patient With Primary Sclerosing Cholangitis and a Liver Transplant: Report of a Case and Review of the Literature , 2006, Diseases of the colon and rectum.

[92]  K. Zatloukal,et al.  Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. , 2006, The American journal of pathology.

[93]  K. Zatloukal,et al.  24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. , 2006, Gastroenterology.

[94]  W. Stremmel,et al.  The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis , 2006, European journal of gastroenterology & hepatology.

[95]  K. Boberg,et al.  High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. , 2005, Gastroenterology.

[96]  L. Rybicki,et al.  The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis , 2005, Alimentary pharmacology & therapeutics.

[97]  M. Vieth,et al.  Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate treatment , 2005, Gut.

[98]  G. Gores,et al.  The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis , 2005, Digestive Diseases and Sciences.

[99]  Tsutomu Masaki,et al.  Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[100]  R. Chapman,et al.  Review article: current management of primary sclerosing cholangitis , 2005, Alimentary pharmacology & therapeutics.

[101]  A. Bergquist,et al.  Increased prevalence of primary sclerosing cholangitis among first-degree relatives. , 2005, Journal of hepatology.

[102]  A. Zinsmeister,et al.  PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis , 2004, Gut.

[103]  M. Färkkilä,et al.  Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebo‐controlled trial , 2004, Hepatology.

[104]  T. Therneau,et al.  A Comparison of Routine Cytology and Fluorescence in situ Hybridization for the Detection of Malignant Bile Duct Strictures , 2004, The American Journal of Gastroenterology.

[105]  H. Tilg,et al.  Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. , 2004, Gastroenterology.

[106]  B. Petersen,et al.  Cost‐minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis , 2004, Hepatology.

[107]  E. Kaltenthaler,et al.  A systematic review and economic evaluation of magnetic resonance cholangiopancreatography compared with diagnostic endoscopic retrograde cholangiopancreatography. , 2004, Health Technology Assessment.

[108]  S. Wigmore,et al.  ROUX-EN-Y Choledochojejunostomy is the method of choice for biliary reconstruction in liver transplantation for primary sclerosing cholangitis , 2004, Transplantation.

[109]  T. Therneau,et al.  Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. , 2003, Gastroenterology.

[110]  P. Marotta,et al.  Liver transplantation for primary sclerosing cholangitis. , 2003, Transplantation proceedings.

[111]  L. Tsui,et al.  Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis , 2003, Human Genetics.

[112]  K. Lindor,et al.  Is there a role for liver biopsy in primary sclerosing cholangitis? , 2003, American Journal of Gastroenterology.

[113]  R. Chapman The management of primary sclerosing cholangitis , 2003, Clinics in liver disease.

[114]  K. Boberg,et al.  Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis , 2002, Gut.

[115]  D. Jewell,et al.  Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study , 2002, Gut.

[116]  J. Reitsma,et al.  Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population , 2002, Gut.

[117]  T. Ang,et al.  Clinical profile of primary sclerosing cholangitis in Singapore , 2002, Journal of gastroenterology and hepatology.

[118]  S. Sumitran-Holgersson,et al.  High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6 , 2002, Gut.

[119]  P. Heidenreich,et al.  Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. , 2002, Gastrointestinal endoscopy.

[120]  K. Lindor,et al.  Small‐duct primary sclerosing cholangitis: A long‐term follow‐up study , 2002, Hepatology.

[121]  G. Gores,et al.  In primary sclerosing cholangitis, gallbladder polyps are frequently malignant , 2002, American Journal of Gastroenterology.

[122]  A. Bergquist,et al.  Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. , 2002, Journal of hepatology.

[123]  P. Sauer,et al.  Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. , 2002, Journal of hepatology.

[124]  D. Adams,et al.  Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease , 2002, The Lancet.

[125]  K. Boberg,et al.  Cholangiocarcinoma in Primary Sclerosing Cholangitis: Risk Factors and Clinical Presentation , 2002, Scandinavian journal of gastroenterology.

[126]  R. Chapman,et al.  A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. , 2001, Gastroenterology.

[127]  D. Adams,et al.  MAdCAM‐1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM‐1 in chronic inflammatory liver disease) , 2001, Hepatology.

[128]  T. Karlsen,et al.  Primary sclerosing cholangitis , 2001, The Lancet.

[129]  W. Kremers,et al.  Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. , 2001, Gastroenterology.

[130]  M. Kimmey,et al.  Ursodiol Use Is Associated with Lower Prevalence of Colonic Neoplasia in Patients with Ulcerative Colitis and Primary Sclerosing Cholangitis , 2001, Annals of Internal Medicine.

[131]  K. Lindor,et al.  Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. , 2000, Journal of hepatology.

[132]  N. LaRusso,et al.  A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis , 2000, American Journal of Gastroenterology.

[133]  C. Benz,et al.  [Primary sclerosing cholangitis]. , 2000, Der Internist.

[134]  B. Petersen,et al.  Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis , 2000, American Journal of Gastroenterology.

[135]  N. LaRusso,et al.  High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis , 2000, American Journal of Gastroenterology.

[136]  K. Lindor,et al.  Serum autoantibodies in patients with primary sclerosing cholangitis. , 2000, Journal of hepatology.

[137]  R. N. Macsween,et al.  Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease. , 1999, Liver.

[138]  G. Gores,et al.  Long‐term results of patients undergoing liver transplantation for primary sclerosing cholangitis , 1999, Hepatology.

[139]  I. Durieu,et al.  Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study. , 1999, Journal of hepatology.

[140]  K. Boberg,et al.  HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. , 1999, Tissue antigens.

[141]  K. Batts,et al.  Recurrence of primary sclerosing cholangitis following liver transplantation , 1999, Hepatology.

[142]  J. Ebbesen,et al.  [Incidence and prevalence of autoimmune liver diseases]. , 1998, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[143]  P. Scheuer,et al.  Ludwig Symposium on biliary disorders--part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis. , 1998, Mayo Clinic proceedings.

[144]  P. Scheuer Pathologic Features and Evolution of Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis , 1998 .

[145]  K. Lindor Ursodiol for Primary Sclerosing Cholangitis , 1997 .

[146]  T. Therneau,et al.  A revised natural history model for primary sclerosing cholangitis. , 1997, Mayo Clinic proceedings.

[147]  Å. Danielsson,et al.  Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. , 1996, Gut.

[148]  N. LaRusso,et al.  Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. , 1996, Gut.

[149]  L. Eriksson,et al.  Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential , 1995, Hepatology.

[150]  Å. Danielsson,et al.  Colchicine treatment of primary sclerosing cholangitis. , 1995, Gastroenterology.

[151]  R. Hultcrantz,et al.  HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis. , 1995, Gastroenterology.

[152]  S. Yamada,et al.  Small duct cholangitis induced byn-formyll-methioninel-leucinel-tyrosine in rats , 1994, Journal of Gastroenterology.

[153]  S. Jalkanen,et al.  Induction and function of vascular adhesion protein-1 at sites of inflammation , 1993, The Journal of experimental medicine.

[154]  R. Vaughan,et al.  Amino acid substitutions at position 38 of the DRβ polypeptide confer susceptibility to and protection from primary sclerosing cholangitis , 1992 .

[155]  H. Waldum Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. , 1992, Journal of hepatology.

[156]  R. Sartor,et al.  Hepatobiliary injury associated with experimental small-bowel bacterial overgrowth in rats , 1991, Immunologic research.

[157]  A. Zinsmeister,et al.  Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. , 1990, Gastroenterology.

[158]  R. Wiesner,et al.  Gallbladder disease in patients with primary sclerosing cholangitis. , 1988, AJR. American journal of roentgenology.

[159]  R. Wiesner,et al.  Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis. , 1986, Gastroenterology.

[160]  R. Wiesner,et al.  Primary sclerosing cholangitis: findings on cholangiography and pancreatography. , 1983, Radiology.

[161]  C. Holdsworth,et al.  Bacteriological and endotoxin studies in cases of ulcerative colitis submitted to surgery. , 1980, Gut.

[162]  R. Chapman,et al.  Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. , 1980, Gut.

[163]  G. Kaplan,et al.  AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Incidence of Primary Sclerosing Cholangitis: a Systematic Review and Meta-Analysis , 2011 .

[164]  K. Lindor,et al.  Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[165]  Christian Gieger,et al.  Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci , 2011, Nature Genetics.

[166]  K. Lindor,et al.  What's Hot in the Red Journal This Month , 2011, The American Journal of Gastroenterology.

[167]  G. Gores,et al.  AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Long-Term Outcomes of Positive Fluorescence In Situ Hybridization Tests in Primary Sclerosing Cholangitis , 2009 .

[168]  K. Zatloukal,et al.  AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Side Chain Structure Determines Unique Physiologic and Therapeutic Properties of norUrsodeoxycholic Acid in Mdr2 / Mice , 2009 .

[169]  F. Lammert,et al.  EASL Clinical Practice Guidelines: management of cholestatic liver diseases. , 2009, Journal of hepatology.

[170]  J. Hasday,et al.  Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease. , 2006 .

[171]  M. Kaplan,et al.  A Pilot Study of Etanercept in the Treatment of Primary Sclerosing Cholangitis , 2004, Digestive Diseases and Sciences.

[172]  K. Itoh,et al.  Autoimmune pancreatitis and multiple bile duct strictures treated effectively with steroid , 2003, Journal of Gastroenterology.

[173]  K. Lindor Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. , 1997, The New England journal of medicine.

[174]  J. Rodés,et al.  Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. , 1994, Journal of hepatology.

[175]  R. Chapman,et al.  HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis. , 1994, Gastroenterology.

[176]  A. Parés,et al.  Epidemiology of primary sclerosing cholangitis in Spain , 1994 .

[177]  R. Vaughan,et al.  Amino acid substitutions at position 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. , 1992, Hepatology.